The question marks surrounding the WTA’s new mandatory genetic sex testing policy

The Women’s Tennis Association (WTA) has recently introduced mandatory genetic sex testing for all players who compete on the WTA Tour.

The change comes as part of the latest revision to the female players’ eligibility policy, which came into effect on Tuesday 21 July. Players will now be required to take one lifetime test by providing a saliva, blood, or cheek swab sample to test for the presence of the SRY gene, a gene present on the Y chromosome responsible for the initiation of male sex characteristics. Only a negative result will permit them to continue playing; if a player tests positive, further medical examination will be undertaken before participation is allowed. Under the guidelines of the policy, even a small but detectable male-typical hormonal exposure, in the first six weeks of a woman’s life, could now prevent her from competing on the Women’s Tour.

The WTA recognises that this is a sensitive and complex issue and is committed to treating all players with dignity

The Women’s Tennis Association

While the policy opens with affirmative language detailing the Tour’s commitment to creating an inclusive environment for all trans and intersex athletes, it also requires players to sign documentation that stipulates they may face disciplinary action if they refuse to be tested. In effect, it begins to categorise athletes into just two kinds, which may not reflect how the athletes themselves identify.

It marks a dramatic shift backwards from the WTA’s previous policy in 2024, which allowed transgender women to compete on the Tour if their testosterone levels were lowered to below 2.5 nmol/L continuously for two years running.

When quizzed on the policy’s evolution, the governing body responded: “The WTA recognises that this is a sensitive and complex issue and is committed to treating all players with dignity and implementing the policy in a respectful and thoughtful way.”

The WTA elucidated that the policy differentiates between biological sex and gender identity, and that there is “no intent to disrespect or question the gender identity or the dignity of any person”.

There are currently no transgender women competing on the WTA tour

Sex determination is far from black-or-white, and chromosomal tests like this one have raised a false alarm for female athletes before. Spanish hurdler María José Martínez Patiño failed a chromosomal test in 1986, due to suffering from Complete Androgen Insensitivity Syndrome (CAIS), which meant she had XY chromosomes present in her body. However, due to the nature of the syndrome, it granted her no competitive advantage, yet she was still ruled ineligible to compete. Conditions like CAIS mean an individual can carry male genetic markers (like the aforementioned SRY gene) yet develop completely female anatomy and derive no hormonal boost.

Perhaps the most striking fact overshadowing this rule change is that there are currently no transgender women competing on the WTA tour, and there haven’t been for 50 years. The only transgender woman who has ever competed was Renee Richards, who reached a grand slam doubles final aged 43, but never inspired a successor. It appears that the WTA has undertaken major policy change for a (currently) completely imagined problem.

The timing of the Association’s policy pivot should come as no surprise as the newest World Athletics regulations, which came into force last September, also requires the same SRY gene testing for athletes to complete. There have been increased efforts amongst the world’s elite sporting associations to tighten regulations surrounding the eligibility of transgender athletes ahead of the LA 2028 Olympic Games.

No players on tour have come forward to protest the policy change thus far – it will be a waiting game to see how the new rules play out.